

North Central Cancer Treatment Group

N04C2, An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR[®] Depot) for Symptomatic Ascites in Cancer Patients

Update 2 – July 10, 2009

Summary

Administrative/editorial changes.

Replacement pages are included. Please incorporate into the protocol and keep this update with your protocol.

Title page Updated NCI version date and addition of Update 2 have been added.

Protocol Resource Page

Page 2: Roxann Neumann's contact information has been added to the table under **Non-paraffin biospecimens:**
Roxann Neumann, RN, BSN, CCRP
NCCTG Research Base Biospecimen Resource Manager
Phone: (507) 538-0602
Fax: (507) 266-0824
Email: neumann.roxann@mayo.edu

Section 14.0 **Translational/Pharmacologic Studies**

Page: 19-20 In order to reflect current contact information, Sections 14.1111 and 14.114 have been updated as follows:

14.1111 Kits will be supplied through ~~MCLCT~~ **MML**. Participating institutions may obtain kits by faxing the Supply Order Form (found in the Forms Packet) to the number listed on the form.

14.114 ~~MCLCT-MML~~ at Mayo Clinic Rochester will receive the samples and send to the Biospecimen, Accessioning, and Processing (BAP) laboratory, Stabile 13-10A, attention BAP Supervisor.